6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00273351 (ClinicalTrials.gov)	January 2006	4/1/2006	Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families	Assessment of Pre-symptomatic and Symptomatic Patients With Parkinson Disease to Identify and Characterize Genetic and Phenotypic Biomarkers for Disease Onset and Progression.	Parkinson Disease;Parkinsonian Syndrome	Drug: [123I]B-CIT	Institute for Neurodegenerative Disorders	Department of Defense;Molecular NeuroImaging	Completed	21 Years	N/A	Both	62	Phase 2	United States
2	NCT00096720 (ClinicalTrials.gov)	February 2004	12/11/2004	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease	Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's	Parkinson Disease;Parkinsonian Syndrome	Drug: levodopa;Drug: Mirapex (pramipexole);Procedure: [123I]ß-CIT and SPECT imaging	Institute for Neurodegenerative Disorders	Boehringer Ingelheim;Department of Defense	Completed	30 Years	N/A	Both	112	Phase 2	United States
3	NCT00209508 (ClinicalTrials.gov)	November 2002	13/9/2005	2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy.	Parkinson's Disease	Drug: GPI 1485	Eisai Inc.	Symphony Neuro Development Company	Completed	40 Years	80 Years	Both	200	Phase 2	NULL
4	NCT00134784 (ClinicalTrials.gov)	April 2000	23/8/2005	Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression	[123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's Disease	Parkinson Disease	Drug: [123I]B-CIT SPECT imaging	Institute for Neurodegenerative Disorders	United States Department of Defense	Completed	22 Years	N/A	All	142	Phase 2	NULL